New hope for Hard-to-Treat breast cancer: Triple-Drug combo shows promise
NCT ID NCT04721977
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding tucatinib to standard drugs trastuzumab and capecitabine can shrink tumors in people with advanced HER2+ breast cancer who have already tried several treatments. About 66 participants will receive the three-drug combination. The main goal is to see if the tumor response rate exceeds 20%.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tucatinib (Tukysa) combined with trastuzumab (Herceptin) and capecitabine (Xeloda)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced HER2+ breast cancer who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial (66 people) with no placebo group, so results may not apply broadly. Side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital ( Site 1013)
Nagoya, Aichi-ken, 464-8681, Japan
-
Fukushima Medical University Hospital ( Site 1012)
Fukushima, 960-1295, Japan
-
Hiroshima City Hiroshima Citizens Hospital ( Site 1024)
Hiroshima, 730-8518, Japan
-
Hokkaido University Hospital ( Site 1022)
Sapporo, Hokkaido, 060-8648, Japan
-
Hyogo Cancer Center ( Site 1005)
Akashi, Hyōgo, 673-8558, Japan
-
Hyogo College of Medicine Hospital ( Site 1019)
Nishinomiya, Hyōgo, 663-8501, Japan
-
Juntendo University Hospital ( Site 1025)
Tokyo, 113-0033, Japan
-
Kanagawa Cancer Center ( Site 1010)
Yokohama, Kanagawa, 241-8515, Japan
-
Kumamoto Shinto General Hospital ( Site 1007)
Kumamoto, 862-8655, Japan
-
Medical Corporation Nahanishikai Nahanishi Clinic ( Site 1016)
Naha, Okinawa, 901-0154, Japan
-
Nagoya University Hospital ( Site 1021)
Nagoya, Aichi-ken, 466-8560, Japan
-
National Cancer Center Hospital ( Site 1003)
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East ( Site 1002)
Kashiwa, Chiba, 2778577, Japan
-
National Cheng Kung University Hospital ( Site 3000)
Dawan, Tainan, 704, Taiwan
-
National Hospital Organization Hokkaido Cancer Center ( Site 1017)
Sapporo, Hokkaido, 003-0804, Japan
-
National Hospital Organization Kyushu Cancer Center ( Site 1009)
Fukuoka, 811-1395, Japan
-
National Hospital Organization Osaka National Hospital ( Site 1001)
Osaka, 540-0006, Japan
-
National Hospital Organization Shikoku Cancer Center ( Site 1014)
Matsuyama, Ehime, 791-0280, Japan
-
Osaka International Cancer Institute ( Site 1004)
Osaka, 541-8567, Japan
-
Saitama Cancer Center ( Site 1018)
Kitaadachi-gun, Saitama, 362-0806, Japan
-
Samsung Medical Center ( Site 2002)
Seoul, 06351, South Korea
-
Seoul National University Hospital ( Site 2003)
Seoul, 03080, South Korea
-
Severance Hospital ( Site 2001)
Seoul, 03722, South Korea
-
Showa University Hospital ( Site 1023)
Tokyo, 142-8666, Japan
-
Social medical corporation Hakuaikai Sagara Hospital ( Site 1008)
Kagoshima, 892-0833, Japan
-
The Cancer Institute Hospital of JFCR ( Site 1015)
Tokyo, 135-8550, Japan
-
Tokyo Medical University Hospital ( Site 1006)
Tokyo, 160-0023, Japan
-
University of Tsukuba Hospital ( Site 1020)
Tsukuba, Ibaraki, 305-8576, Japan